Global EPO Biosimilars Market Outlook 2018 -




Published: February 2014 | Pages: 45

The biosimilars industry has been growing stupendously across the globe for the past few years. Increasing healthcare costs, major blockbuster drugs about to go off patent and rising aging population are driving this industry, which stands at a vivid position, and is expected to evolve greatly from its current state. With the governments and private players worldwide stepping into this industry, the market shows bright prospects and immense opportunities to cash in on.

 
As per the estimations of our latest report, “Global EPO Biosimilars Market Outlook 2018”, the global EPO biosimilars market will grow at a CAGR of around 37% during 2013-2018.  Our report provides a thorough study of the EPO biosimilars market, and its future outlook. Firstly, we have provided a basic overview of the total biologics market, along with its current and future size. Next, we have highlighted some of the major trends and drivers which would be responsible for shaping the global biosimilars market. Some of these trends are rising collaborations among major pharma players and strong government support to encourage the growth of biosimilars. This is then followed by the total biosimilars market and its future size. The key segments of this market and their respective shares have also been highlighted.

 
Finally, we have given a brief introduction of the global EPO biosimilars market, its estimated size and future value. The market is about to witness rapid growth as a result of major blockbuster drugs losing their patents in 2013 and 2014. We have also provided a list of the marketed EPO biosimilars and those that are in the pipeline.

 
At the end, key players of the EPO biosimilars market have been profiled where focus has been on their business overview, key products and those in the pipeline of the companies. Overall, the report aims at providing reliable and complete information about the EPO biosimilars market to clients and potential investors.

 
1. Analyst View
2. Research Methodology
3. Biologics Market Outlook to 2018
     3.1 Market Size
     3.2 Market Segmentation
4. Market Trends & Drivers
     4.1 Emerging Markets to Play a Pivotal Role in the Growth of Biosimilars
     4.2 Rising Business Alliances Aiding in Biosimilar Development
     4.3 Governments Realizing the Potential in Biosimilars, Encouraging Industry Growth
5. Biosimilars Market Outlook to 2018
6. Erythropoietin Market Outlook to 2018
     6.1 Scientific Insight
     6.2 Market Analysis
     6.3 EPO Biosimilars Products - Marketed and Under-Pipeline
7. Competitive Landscape
     7.1 Hospira
     7.2 Sandoz GmbH
     7.3 Stada
     7.4 Hexal AG
     7.5 Medice Arzneimittel Pütter GmbH & Co.
     7.6 Teva
     7.7 LG Life Sciences
     7.8 Dr. Reddy's Labs (DRL)
     7.9 Biocon
     7.10 Intas Pharmaceuticals
     7.11 Reliance Life Sciences
     7.12 3 SBio Inc

 
List of Figures

 
Figure 3-1: Global - Biologics Market (Billion US$), 2012-2018
Figure 3-2: Global - Biologics Market by Segment (%), 2012
Figure 5-1: Global - Biosimilars Market (Billion US$), 2012 & 2018
Figure 5-2: Global - Biosimilars Market by Key Segment (%), 2012
Figure 6-1: Global - EPO Biosimilars Market (Billion US$), 2012-2018
Figure 6-2: Global - EPO Biosimilar Market by Player (%), 2012

 
List of Tables

 
Table 6-1: Global - Marketed EPO Biosimilar Products of Key Players
Table 6-2: Global - Pipeline EPO Biosimilar Products of Key Players